<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04978779</url>
  </required_header>
  <id_info>
    <org_study_id>VNC-152-102</org_study_id>
    <nct_id>NCT04978779</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome</brief_title>
  <official_title>An Open-label, Multicenter Phase 1 Dose Escalation Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics, and Maximum Tolerated Dose of VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vincerx Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vincerx Pharma, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and&#xD;
      recommended phase 2 dose (RP2D) of VIP152 in patients with Chronic Lymphocytic Leukemia (CLL)&#xD;
      or Richter Syndrome&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>End of Cycle 1/ Day 21</time_frame>
    <description>Incidence of Dose Limiting Toxicities (DLT) of VIP152</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Number of participants with adverse events as a measure safety and tolerability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 Dose</measure>
    <time_frame>End of Cycle 1/Day 21</time_frame>
    <description>Recommended Phase 2 dose of VIP152 in CLL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor Response</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Tumor response evaluation based on the response criteria as applicable for CLL and Richter Syndrome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Time at Which Response Criteria are Met for Complete Response or Partial Response (Whichever Occurs First) Until the First Date of Recurrence, Progression or Death per applicable response criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Number of Participants Without Disease Progression per iwCLL guidelines for CLL &amp; Lugano Classification for NHL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Overall Survival Rate, Defined as Time Between First Dose Date and Date of Death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Relapsed Non Hodgkin Lymphoma</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Refractory Chronic Lymphocytic Leukemia</condition>
  <condition>Richter Syndrome</condition>
  <condition>MYC Amplification</condition>
  <condition>MYC Overexpression</condition>
  <condition>MYC Translocation</condition>
  <arm_group>
    <arm_group_label>Dose escalation of VIP152 Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigating VIP152 in a dose escalation cohort in patients with CLL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose expansion of VIP152 Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigating VIP152 in a dose expansion cohort in patients with CLL and Richter Syndrome.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VIP152</intervention_name>
    <description>Weekly IV infusion (30 minute) for 21 day cycles.</description>
    <arm_group_label>Dose escalation of VIP152 Escalation</arm_group_label>
    <arm_group_label>Dose expansion of VIP152 Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients aged &gt;/=18 years&#xD;
&#xD;
          -  Patients with a histologically or cytologically:&#xD;
&#xD;
               -  Confirmed CLL who are refractory to or have progressed from 2 or more regimens&#xD;
                  including BTKi and venetoclax or&#xD;
&#xD;
               -  Confirmed CLL transformed to DLBCL (Richter Syndrome) who have relapsed after, or&#xD;
                  been refractory, to at least 1 prior line of therapy for the DLBCL and having MYC&#xD;
                  overexpression/amplification/translocation&#xD;
&#xD;
          -  Adequate bone marrow, liver, and renal functions&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active clinically serious infections of Grade &gt; 2; requiring parenteral therapy&#xD;
&#xD;
          -  Subjects who have new or progressive brain or meningeal or spinal metastases.&#xD;
&#xD;
          -  Anticancer chemotherapy or immunotherapy during the study or within one week prior to&#xD;
             the first dose of study drug&#xD;
&#xD;
          -  Major surgery or significant trauma within 4 weeks before the first dose of study drug&#xD;
&#xD;
          -  Allogeneic bone marrow transplant or stem cell rescue within 4 months before first&#xD;
             dose of study drug; patients must have completed immunosuppressive therapy before&#xD;
             enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincerx Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Vincerx Pharma, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vincerx Clinical Trials Contact</last_name>
    <phone>+(1) 650-880-6676</phone>
    <email>clinicaltrials@vincerx.com</email>
  </overall_contact>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 15, 2021</study_first_submitted>
  <study_first_submitted_qc>July 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2021</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CLL</keyword>
  <keyword>Leukemia</keyword>
  <keyword>CDK-9</keyword>
  <keyword>VIP152</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

